Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
Agreement Adds to Shionogi’s Growing Pipeline in Rare Disease MZE001 has the Potential to be the First Oral Therapy for...




















